What is Trinomab(Zhuhai) worth?
$533.7Mlast known valuation
Free account
See the evidence behind this price
- ·The complete investor list — 27 names
- ·Watchlist + deal alerts for Trinomab(Zhuhai)
- ·The full record, as it builds
Create free account
No card required
Funding history
No rounds on record
No funding rounds for Trinomab(Zhuhai) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Pro members can request priority coverage with a 48-hour turnaround.
How Trinomab(Zhuhai)'s valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Trinomab(Zhuhai), too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →
Frequently asked
- What is Trinomab(Zhuhai) worth?
- Trinomab(Zhuhai)'s last known valuation is $533.7M.
- How much has Trinomab(Zhuhai) raised?
- Trinomab(Zhuhai) has raised $221.2M in total funding across its recorded rounds.